

NYMOX PHARMACEUTICAL CORP
Form 4
March 25, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Robinson James George

2. Issuer Name and Ticker or Trading Symbol
NYMOX PHARMACEUTICAL CORP [NYMX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
03/21/2016

Director 10% Owner
 Officer (give title below) Other (specify below)

10 EAST LEE STREET, SUITE 2705

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

BALTIMORE, MD 21202

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|-----------|---------|
| | | | Code | V | Amount | (A) or (D) | Price | | |
| Common Stock | 03/21/2016 | 03/21/2016 | P | | 1,500 | A | \$ 2.31 | 2,659,050 | D |
| Common Stock | | | | | | | | 45,050 | I Trust |
| Common Stock | 03/21/2016 | 03/21/2016 | P | | 1,000 | A | \$ 2.34 | 2,660,050 | D |
| Common Stock | | | | | | | | 45,050 | I Trust |
| Common Stock | 03/21/2016 | 03/21/2016 | P | | 2,000 | A | \$ 2.28 | 2,662,050 | D |

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form 4

| | | | | | | | | | |
|--------------|------------|------------|---|-------|---|---------|-----------|---|-------|
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/21/2016 | 03/21/2016 | P | 2,500 | A | \$ 2.3 | 2,664,550 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/21/2016 | 03/21/2016 | P | 2,500 | A | \$ 2.29 | 2,667,050 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/21/2016 | 03/21/2016 | P | 3,500 | A | \$ 2.29 | 2,670,550 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/22/2016 | 03/22/2016 | P | 2,500 | A | \$ 2.34 | 2,673,050 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/22/2016 | 03/22/2016 | P | 3,500 | A | \$ 2.38 | 2,676,550 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/22/2016 | 03/22/2016 | P | 3,500 | A | \$ 2.31 | 2,680,050 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/23/2016 | 03/23/2016 | P | 4,500 | A | \$ 2.34 | 2,684,550 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/23/2016 | 03/23/2016 | P | 4,500 | A | \$ 2.23 | 2,689,050 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/24/2016 | 03/24/2016 | P | 3,500 | A | \$ 2.19 | 2,692,550 | D | |
| Common Stock | | | | | | | 45,050 | I | Trust |
| Common Stock | 03/24/2016 | 03/24/2016 | P | 5,000 | A | \$ 2.21 | 2,697,550 | D | |
| | | | | | | | 45,050 | I | Trust |

